March 2024 - QualityStocks

ThursdayMar 28, 2024 3:42 pm

QualityStocksNewsBreaks – Diamond Lake Minerals Inc. (DLMI) Positioned ‘Ahead of the Curve’ in Tokenization

Diamond Lake Minerals (OTC: DLMI) is a leading multi-strategy operating company specializing in developing and supporting digital assets and SEC-registered security tokens. The company was featured in a new Benzinga Crypto article that discussed DLMI’s favorable positioning in tokenization attributed to its innovative technology, infrastructure and leadership. “DLMI has spent a substantial amount of time and resources under the leadership of its CEO Brian J. Esposito working on the program of converting real estate assets into blockchain-based digital tokens in its ecosystem… A big part of DLMI’s strategy was its recent acquisition of Avrio Worldwide PBC, a registered market infrastructure…

ThursdayMar 28, 2024 2:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Capitalizing on ‘Overwhelming Interest’ to Focus on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. “This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH technology including its new foray into GLP-1 drugs… This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage…

ThursdayMar 28, 2024 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024 The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for…

ThursdayMar 28, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029. Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost the profitable yield of hemp and cannabis production The United States has seen a rising awareness of the health and therapeutic benefits of cannabinoids, prompting an expected market increase of 15.3%, from $22.23 billion in…

WednesdayMar 27, 2024 2:51 pm

QualityStocksNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Kicks Off First in Behavioral Health Webinar Series Today, Register Now

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol-detection solutions, is hosting the first segment of its new behavioral-health webinar series. Titled "The Future of Alcohol Monitoring Is Here: Discover Touch-Based Detection with SOBRsafe," the webinar begins today at 3 p.m. ET. The webinar is hosted by recovery advocate and TV personality Jason Wahler and features experts in the field, including Keenen Diamond, president and COO of Oceanfront Recovery; Wendy Stine, a certified interventionist and addictions counselor; and Matt Mitchell, transdermal technology veteran and director of partnerships for SOBRsafe. To register for the webinar, visit https://ibn.fm/MdgTr To view the full press…

WednesdayMar 27, 2024 2:39 pm

QualityStocksNewsBreaks – Turbo Energy S.A. (NASDAQ: TURB) Offers ‘Best-on-the-Market’ AI and Optimization System

Turbo Energy (NASDAQ: TURB), a designer, developer and manufacturer of photovoltaic energy generation, management and storage equipment, is harnessing artificial intelligence (“AI”) within its solar energy solutions. “The company’s ‘SunBox Home’ system encompasses an all-in-one AI-powered energy storage solution designed to assist households in managing their power consumption. Directly linked to a household’s solar panel generation unit, the SunBox system allows users to choose between settings including ‘maximum consumption’ or ‘maximum savings,’ conserve a portion of its energy reserves in the event of unexpected electricity blackouts or, rather, sell excess power back onto the grid. The groundbreaking system additionally boasts…

WednesdayMar 27, 2024 1:58 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. “The company’s lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (‘CRRT’) machines already installed in hospitals and clinics. The device incorporates a formulation of adsorbent components to optimize the broad-spectrum reduction of viral pathogens, bacterial toxins and inflammatory mediators from the bloodstream,” a…

WednesdayMar 27, 2024 1:52 pm

QualityStocksNewsBreaks – Beyond Air Inc. (NASDAQ: XAIR) Reports on $16M Registered Direct Offering with Health-Care Focused Investors

Beyond Air(R) (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (“NO”) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors, has entered into a securities purchase agreement. The agreement is with healthcare-focused institutional investors and accredited investors, including certain directors and officers of the company. According to the agreement, investors have agreed to purchase 9,638,556 shares of the company’s common stock and warrants at a purchase price of $1.66 per share and accompanying warrant, resulting in gross proceeds of approximately $16 million,…

WednesdayMar 27, 2024 1:08 pm

QualityStocksNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Awarded New California-Based Project Valued at up to $2M

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT and cybersecurity sectors, has announced that its fully owned subsidiary, Leaders in Community Alternatives (“LCA”), has won a new project in California, valued at up to $2 million. As part of the project, LCA will provide a comprehensive jail-based program focusing on re-entry services for adult inmates, designed to support individuals transitioning back into the community. “This award marks an exciting expansion to a new county for SuperCom and underscores our unwavering commitment to enhancing public safety in new territories. This achievement reflects our proven expertise…

WednesdayMar 27, 2024 1:03 pm

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, through its subsidiary, HUGE Biopharma Australia Pty Ltd., entered into agreement with iNGENu CRO Pty Ltd. The agreement outlines plans to conduct a phase 1 study. The randomized, double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants. A patented new chemical entity, Lucid-21-302 is a first-in-class, nonimmunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis…

Site Search

Company Search

Month: March 2024